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The potential of poly (lactic-co-glycolic) acid (PLGA) microparticles as carriers 
for vascular endothelial growth factor (VEGF) has been demonstrated in a previous 
study by our group, where we found improved angiogenesis and heart remodeling in a 
rat myocardial infarction model (Formiga et al., 2010). However, the observed 
accumulation of macrophages around the injection site suggested that the efficacy of 
treatment could be reduced due to particle phagocytosis.  
The aim of the present study was to decrease particle phagocytosis and 
consequently improve protein delivery using stealth technology. PEGylated 
microparticles were prepared by the double emulsion solvent evaporation method using 
TROMS (Total Recirculation One Machine System). Before the uptake studies in 
monocyte-macrophage cells lines (J774 and Raw 264.7), the characterization of the 
microparticles developed was carried out in terms of particle size, encapsulation 
efficiency, protein stability, residual poly(vinyl alcohol) (PVA) and in vitro release. 
Microparticles of suitable size for intramyocardial injection (5 μm) were obtained by 
TROMS by varying the composition of the formulation and TROMS conditions with 
high encapsulation efficiency (70-90%) and minimal residual PVA content (0.5%). 
Importantly, the bioactivity of the protein was fully preserved. Moreover, PEGylated 
microparticles released in phosphate buffer 50% of the entrapped protein within 4 hours, 
reaching a plateau within the first day of the in vitro study. Finally, the use of PLGA 
microparticles coated with PEG resulted in significantly decreased uptake of the carriers 
by macrophages, compared with non PEGylated microparticles, as shown by flow 
cytometry and fluorescence microscopy. 
On the basis of these results, we concluded that PEGylated microparticles loaded with 
VEGF could be used for delivering growth factors in the myocardium. 
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The concept of stealth technology came into being during the World War II in 
the attempt to escape from radar control. Ever since then, stealth strategy has included 
two different approaches: the development of radar absorbing paints, and novel designs 
in terms of shape and size. In the field of drug delivery systems (DDS), this concept has 
been applied to the ability of these carriers to avoid immunological recognition (Wassef 
et al., 1991). As in the military context, the shape (Lin et al., 2011), size (Maldiney et al., 
2011) and material properties (Essa et al., 2011; Zhu et al., 2011) of the delivery system 
are crucial.  
Recently, some research showing how macrophages have a higher affinity for 
specific shapes and sizes has been published (Doshi and Mitragotri, 2010). In this paper 
the authors conclude that particles with a size greater than 4 µm suffer less protein 
adsorption, which is the stage prior to macrophage phagocytosis. Interestingly, when 
comparing these results with the size distribution of bacteria, they found that most of 
these have a size between 2 and 3 µm, which favors their opsonization.    
In 1978, Van Oss (Van Oss, 1978) described the phagocytosis process as a 
surface phenomenon, demonstrating how bacteria that are more hydrophobic than 
phagocytes readily become phagocytized, whereas bacteria that are more hydrophilic 
than phagocytes resist phagocytosis. At that time, researchers proposed the surface 
modification of molecules, by making them more hydrophilic, as a strategy to reduce 
phagocytic removal. In the 1970s, pegnology, the art of surface-modifying proteins, 
drugs or DDS by attaching molecules of poly(ethylene glycol) (PEG) was proposed by 
Abraham Abuchowski and Frank F. Davis (Abuchowski et al., 1977), and this has been 
applied effectively in protein therapies, obtaining increased stability (Khondee et al., 
2011), increased resistance to proteolytic inactivation (Turner et al., 2011), decreased 
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immunogenicity (Milla et al., 2011), increased circulatory half-lives (Maleki et al., 
2011), and reduced toxicity (Jain, A. and Jain, S.K., 2008), thus improving the delivery 
and efficacy of proteins. To date, incorporating PEG seems to hold the most promising 
benefits while showing the lowest harmful effects (Owens and Peppas, 2006) and 
modified drugs are already on the market, most of which are PEGylated proteins (Pasut 
et al., 2008), such as interferon alpha (Fried et al., 2002), L-asparaginase (Abuchowski 
et al., 1984), granulocyte colony-stimulating factor (Tanaka et al., 1991) and uricase 
(Davis et al., 1981). However, despite the advances in the field of protein therapy, 
stealth technology is still emerging within the area of DDS. In fact, just one PEGylated 
delivery system has come onto the market (Knop et al., 2010): a PEGylated liposome 
containing doxorubicin for the treatment of cancer.  
Our group recently published a study in which poly (lactic-co-glycolic) acid 
(PLGA) microparticles encapsulating the vascular endothelial growth factor (VEGF) 
were intramyocardially implanted in a ischemia-reperfusion animal model (Formiga et 
al., 2010). Benefits of the therapy were observed in terms of enhanced angiogenesis and 
notable reduction of harmful remodeling, but when we studied the continued presence 
of the particles at the injection site over time, a macrophage accumulation around the 
particles depot was observed, which could limit the efficacy of the treatment. To 
overcome this challenge, in the present study our aim was to develop and characterize in 
vitro PEG-PLGA microparticles loaded with VEGF for their subsequent use in 
cardiovascular disease. The uptake of VEGF-PEGylated microparticles was studied by 
flow cytometry and fluorescence microscopy using two different monocyte-macrophage 
cell lines. Non PEGylated PLGA microparticles were used for comparison.    
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2.1. Materials 
Human recombinant VEGF was from R&D Systems (Minneapolis, MN, USA). 
PLGA with a lactic:glycolic ratio of 50:50 Resomer® RG 503H (Mw 34KDa), 
poly[(D,L-lactide-co-glycolide)- co-PEG] diblock Resomer® RGP d 5055 (5% PEG) 
and Resomer® RGP d 50105 (10% PEG) were provided by Boehringer-Ingelheim 
(Ingelheim, Germany). PEG 400, sodium azide, Rhodamine B isothiocyanate and 
human serum albumin (HSA) were provided by Sigma–Aldrich (Barcelona, Spain). 
Dichloromethane and acetone were obtained from Panreac Quimica S.A. (Barcelona, 
Spain). Poly(vinyl alcohol) (PVA), 88% hydrolyzed (MW 125000), was from 
Polysciences, Inc. (WA, USA). Rabbit polyclonal anti-human VEGF-A (clone A-20, sc-
152) was supplied by Santa Cruz Biotechnology (Santa Cruz, CA, USA). ECL™ anti-
Rabbit IgG horseradish peroxidase-linked whole antibody was from Amersham 
Biosciences (Buckinghamshire, UK). Mouse monoclonal anti-rat CD68 was provided 
by AbD Serotec (Oxford, UK). All the Western blot reagents were purchased from 
BioRad unless specified in the text.  
 The murine monocyte-macrophage cells lines J774 and Raw 264.7 were 
provided by Dr. Latasa (CIMA, University of Navarra). Human umbilical venous 
endothelial cells (HUVECs) were extracted from umbilical cords from donors, after 
informed consent according to the guidelines of the Committee on the Use of Human 
Subjects in Research at the Clinic Universidad de Navarra. CellTiter 96® AQueous One 
Solution Cell Proliferation Assay (MTS) was obtained from Promega.  
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VEGF-loaded microparticles were prepared by the double emulsion solvent 
evaporation method using TROMS (Formiga et al., 2010; Garbayo et al., 2009). Briefly, 
the organic solution composed of 4 ml of a mixture of dicloromethane/acetone (3:1) 
containing 50 mg of Resomer RG503 was injected into the inner aqueous phase, which 
consisted of 50 µg of VEGF in 10 mM phosphate, 50 mM sodium chloride (PBS), 5 mg 
of HSA and 5 µl of PEG400. The primary emulsion (W1/O) was recirculated through 
the system for 90 sec under a turbulent regime at a flow rate of 38 ml/min. The first 
emulsion was injected into 20 ml of the external aqueous phase (W2) composed of 20 
ml of a PVA solution resulting in the formation of a double emulsion (W1/O/W2) which 
was homogenized by circulation through the system for 45 sec. The resulting double 
emulsion was stirred at room temperature for at least 3 hours to allow solvent 
evaporation and microparticle formation. Finally, microparticles were washed three 
times with ultrapure water and lyophilized (Genesis 12EL, Virtis). For PEGylated 
microparticles, 50 mg of a mixture of Resomer® 503H and Resomer® RGP d 5055 or 
Resomer® RGP d 50105 (1:1) were dissolved in the organic phase and microparticles 
were prepared as described above 
The composition of the different phases and TROMS parameters were varied to 
achieve an adequate particle size (of around 5 μm) for intramyocardial administration, 
(Formiga et al., 2010).  
 
2.3. Microparticle characterization 
2.3.1. Particle size, size distribution and zeta potential 141 
The mean particle size and size distribution of the microparticles were 142 
determined by laser diffractometry using a Mastersizer-S® (Malvern Instruments, 143 
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Malvern, UK). Microparticles were dispersed in distilled water and analyzed under 144 
continuous stirring. The results were expressed as mean volume, in micrometers. 145 
Samples were measured in triplicate. 146 
The zeta potential was measured using Zetaplus® (Brookhaven instruments, NY, 147 
US). Samples were diluted with distilled water and each experiment was repeated three 148 
times.  149 
150 
151 
 
2.3.2. Residual PVA 
The residual PVA associated with microparticles was determined by a 152 
colorimetric method based on the formation of a colored complex between two adjacent 153 
hydroxyl groups of PVA and an iodine molecule (Joshi et al., 1979). Briefly, 2 mg of 154 
lyophilized microparticles were resuspended in 2 ml of NaOH 0.5 M for 15 min at 155 
60 °C. Each sample was neutralized with 900 μl of 1 N HCl and the volume was 156 
adjusted to 5 ml with distilled water. Next, 3 ml of a 0.65 M solution of boric acid, 0.5 157 
ml of a solution of I2/KI (0.05 M/0.15 M) and 1.5 ml of distilled water were added. 158 
After 15 min of incubation, the absorbance of the samples was measured at 690 nm 159 
using an Agilent 8453 UV–visible spectrophotometer (Agilent Technologies, Palo Alto, 160 
CA, USA). A standard plot of PVA was prepared under identical conditions. 161 
Measurements were performed in triplicate. 162 
163 
164 
 
2.3.3. Drug loading and encapsulation efficiency 
The amount of VEGF encapsulated in the microparticles was determined by 165 
dissolving 1 mg of microparticles in 50 μl of DMSO. VEGF containing samples were 166 
diluted in 350 μl of PBS for western-blot analysis. SDS-PAGE was performed onto 167 
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12% polyacrylamide gels. Following electrophoresis the proteins were transferred onto 168 
nitrocellulose membranes which were then blockaded using 5% nonfat dried milk in 169 
Tris Buffered Saline (TBS) with 0.05% Tween 20, for 1h at room temperature (RT). 170 
Membranes were incubated for 2.5 h at RT with rabbit antihuman VEGF-A antibody 171 
(A-20: sc-152, 1:2000 dilution). The bounded antibody was detected with horseradish 172 
peroxidase (HRP)-conjugated donkey anti-rabbit IgG antibody (1 h, RT, 1:2000 173 
dilution). Chemiluminiscence detection was performed using LumiLight Plus western 174 
blotting substrate (Roche Diagnostics, Mannheim, Germany). The VEGF signal was 175 
quantified by densitometry using the Quantity One software (Bio-Rad Laboratories Inc., 176 
Munich, Germany). Samples containing defined quantities of VEGF were diluted under 177 
the same conditions (PBS and DMSO) and used as standard curve.  178 
179 
180 
 
2.4. In vitro release studies 
VEGF loaded microparticles (1 mg, n=3) were resuspended in 0.25 ml PBS pH 181 
7.4 with 0.02% (w/v) sodium azide used as a bacteriostatic agent. Incubation took place 182 
under orbital shaking in rotating vials (FALC F200, Falc instruments, Treviglio, Italy) 183 
at 37 °C. At predefined times, the tubes were centrifuged (20000 g, 10 min) and the 184 
supernatant was removed and frozen at -80ºC until it was analyzed by western-blot. The 185 
removed solution was replaced with an equal volume of fresh release buffer to maintain 186 
sink conditions. Release profiles were expressed in terms of cumulative release and 187 
plotted versus time. 188 
189 
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2.5. VEGF bioactivity 
The bioactivity of the VEGF released from the microparticles was evaluated in 
vitro by determining the proliferative capacity of a human umbilical vein endothelial 
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cell (HUVECs) after VEGF treatment. Cells were obtained from human umbilical cord 
by 0.1% collagenase II digestion (Jaffe et al., 1973) and expanded in F12K medium 
(ATCC 30-2004) supplemented with 30 μg/mL endothelial cell growth supplement 
(ECGS, BD Biosciences), 10% fetal bovine serum, 1% sodium heparin and 1% 
penicillin/streptomycin.  
For the proliferation assay, the cells were plated into 96-well culture plates at a 
density of 3× 103 cells/well. After 12 hours, cells were treated with 10 and 25 ng/ml of 
free VEGF or released from the microparticles. Culture medium and release medium 
from non-loaded microparticles were used as control. After 72 h incubation time under 
normal culture conditions, proliferation in each group was measured using MTS assay.  
 
2.6. Uptake of microparticles by macrophages 
The microparticle (PEGylated and non-pelylated microparticles) uptake study 
was analyzed in two different monocyte-macrophage cell lines by fluorescence 
microscopy and flow cytometry.  
 
2.6.1. Fluorescence microscopy 
Fluorescent-labeled microparticles with Rhodamin B isothiocyanate (0.5 mg/ml) 
were prepared by adding the marker to the inner aqueous phase. Microparticles were 
prepared as described above. The uptake of fluorescence particles was evaluated in the 
monocyte-macrophage J774 cell line. Cells were plated into a 6 well culture plates at a 
70% confluence in serum free RPMI medium containing 1% penicillin/streptomycin. 
Four hours later culture medium (control), Rhodamine B isothiocyanate PLGA or PEG-
PLGA microparticles were added at a final concentration of 0.33 mg/ml. After 3 hours, 
culture supernatant containing microparticles was removed and the wells were washed 
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three times with PBS. Fluorescence microparticles inside the cells were visualized using 
an EVOSfl fluorescence microscope (Euroclone, Milan, Italy). The fluorescent signal 
(corresponding to particle uptake) was quantified using the ImageJ software. Ten fields 
per well were randomly analyzed (experiments performed in triplicate). The signal 
emitted was normalized to the cell number in each field.  
 
2.6.2. Flow cytometry 
For flow cytometry studies, RAW 264.7 cells were seeded at a 30 % confluence 
in DMEM 10% serum at 37 ºC and allowed to adhere to the 6 well plate for 48 h. Then 
the medium was removed and cells were incubated with serum free DMEM for 4 h. 
PLGA or PEG-PLGA microparticles previously suspended in DMEM were then added 
(0.33 mg/ml), whereas the control group received only DMEM. At different time 
intervals (from 30 minutes up to 3 h) the medium was removed, cells were detached, 
collected and washed three times with PBS. After centrifugation (1500 g, 5 min), the 
cells were suspended and fixed with 2 % formaldehyde solution for their analysis. Cell 
complexity or cell granularity was studied by flow cytometry analysis using a BD 
FACSCalibur flow cytometer for the acquisition of samples. The side scatter (SSC) 
parameter was recorded as reflecting internal properties of cells (e.g. granularity and 
refractive index). Data were analyzed using the CellQuest software.  
 
2.7. Statistics 
Results are expressed as mean ± SD. Statistical significance was tested on the 
basis of Student’s t test at 95 % confidence intervals. 
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3. Results and discussion 243 
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3.1. Preparation of PLGA and PEG-PLGA microparticles 
Among the different methods available for protein encapsulation, TROMS was 
selected because it is a semi-industrial technique capable of encapsulating fragile 
molecules while maintaining their native properties (Formiga et al., 2010; Garbayo et al., 
2008). Since our final goal is to inject the microparticles in the ischemic heart, the aim 
when preparing the polymeric microparticles was to obtain a size between 5 and 8 µm, 
which has been shown to be compatible with intramyocardial administration (Formiga 
et al., 2010).  
During the manufacturing process, size was shown to be affected by polymer 
composition. The best results, in terms of feasibility, reproducibility and adequate 
particle size distribution for intramyocardial injection were obtained with the polymer 
containing 10% of PEG, and so this polymer was selected for the subsequent 
experiments. 
Using the same formulation and maintaining the TROMS parameters to prepare 
PEGylated and non-PEGylated microparticles, the size was increased for the PEG-
PLGA co-polymer. Therefore TROMS parameters, mainly first and second emulsion 
circulation times, were studied in order to achieve PEGylated particles with the desired 
diameter (Table 1). The circulating times selected were 90 seconds for the first emulsion 
and 45 seconds for the second emulsion, obtaining a particle size of approximately 6.6 
µm (Table 2). Other factors were also studied, such as TROMS needle inner diameter, 
polymer % (w/v) in the organic phase and PVA % (w/v) in the external aqueous phase. 
Selected parameters are resumed in Table 2.  
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3.2. Microparticle characterization 268 
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As stated above, particles with an average size close to 6 µm were obtained for 
both types of microparticles, which have been demonstrated to be compatible with 
intramyocardial injection (Formiga et al., 2010). 
As shown in Table 3, surface charge values were negative for PEGylated and 
non-PEGylated particles. However, PEGylated microparticles showed a decreased 
negative charge (-8.79±0.61 mV vs. -18.10±0.71 mV). This may be attributed to the 
presence of the PEG chains in the surface of the particle (Essa et al., 2010). Moreover, it 
has been previously described that a higher PEG chain density on the surface of the 
particles decreases the mobility of the PEG chains and thus decreases the steric 
hindrance properties of the PEG layer (Owens and Peppas, 2006). On the other hand, if 
the PEG concentration is too low, opsonins will attach to the surface and the stealth 
effect will be decreased. Therefore, in order to achieve an intermediate surface chain 
concentration between the “mushroom” and the “brush” conformation (low and high 
PEG concentration respectively), a ratio composition of 1:1 (w/w) of polymers Resomer 
503H: Resomer RGP d 50105 was finally selected (Table 3). 
 
3.2.2. Residual PVA 
PVA contained in the two types of microparticles was less than 2%, being lower 
for the PEGylated microparticles (Table 3). This lower adsorption of PVA in the surface 
modified particles could be explained as a consequence of the increased degree of 
hydrophilicity due to PEG chains, reducing PVA interaction (Essa et al., 2010). In any 
case, these concentrations are much lower than those reported in the literature for PLA 
microparticles (Gref et al., 2001) 
 13
3.3. Drug loading and encapsulation efficiency 293 
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In a previous study, VEGF-PLGA microparticles with high encapsulation 
efficiency were obtained (Formiga et al., 2010). In the present paper, this growth factor 
was entrapped into PEG-PLGA microparticles obtaining very high encapsulation values, 
between 80 and 100 % for both PLGA and PEG-PLGA particles, as determined by 
western-blot. Moreover, western-blot allowed us to confirm that no degradation of 
VEGF occurred during the encapsulation process, showing a single characteristic band 
corresponding to 21 kDa (results not shown).  
The ability to quantify proteins by light emitting chemiluminescence detection 
has been previously studied, highlighting the hotspots which have been taken into 
account in this research (Dickinson and Fowler, 2002). The results of encapsulation 
efficiency obtained were also indirectly confirmed in the bioactivity assays (section 3.5). 
In the cell proliferation study, when treating cells with the protein released from the 
particles, VEGF concentration was calculated considering the encapsulation values. If 
cell proliferation is in accordance with the expected VEGF concentration, it is possible 
to confirm the encapsulation efficiency values, and in this sense the obtained results 
allow us to consider the western-blot technique as a reliable method to measure the 
encapsulation efficiency.  
 
3.4. In vitro release studies 
The amount of VEGF released from the microparticles was measured by an in 
vitro assay, to confirm that the particles really retain the protein for a period of time and 
allow a sustained release.  
When comparing both types of microparticles, the burst effect was higher for the 
PEGylated ones, which released approximately 50 % of VEGF within the first 4 hours, 
 14
while 30 % of the entrapped peptide was released from the PLGA particles (Figure 1). 
Moreover, the plateau was reached after 24 hours for the surface modified particles, 
whereas for the PLGA particles it occurred after three days. This different release 
behavior is attributable firstly to the fact that burst effect is mainly due to the protein 
located in the surface of the particle (Essa et al., 2010; Yoncheva et al., 2009). The 
presence of PEG chains increases the surface of the particle and, as a consequence, a 
greater amount of protein attaches to it. Secondly, as PEG chains are hydrophilic, when 
they are in an aqueous medium, like the release buffer, they are dissolved and this 
makes it easier for the buffer to get into the matrix, allowing the protein to be released. 
In any case, it has to be taken into account that a slower protein release is expected in 
vivo, as previously demonstrated (Blanco-Prieto et al., 2004). The main reason for the 
slower in vivo kinetics is the low availability of water in the tissue compared with the
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vitro conditions, in which the PLGA microparticles are incubated in PBS at 37°C and 
shaken. Moreover, the tissue environment surrounding the microparticles will slow the 
release of VEGF in vivo. 
 
3.5. VEGF bioactivity 
VEGF is a growth factor well known for its angiogenic activity (Carmeliet and 
Jain, 2011). In this sense, it has been demonstrated to promote proliferation of 
endothelial cells.  
In order to confirm that VEGF bioactivity was preserved during the 
encapsulation/release processes, we tested the ability of VEGF released from the 
PEGylated particles to stimulate proliferation of HUVEC. Considering protein load and 
in vitro release profile, cells received the same dose of free VEGF and VEGF released 
from PEGylated microparticles (10 and 25 ng/ml). Both treatments induced the same 
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degree of cell proliferation when compared to control groups (Figure 2). These results 
allow us to conclude that the presence of PEG in the polymer matrix does not alter the 
biological properties of the encapsulated VEGF, as it has been previously demonstrated 
for PLGA microparticles (Formiga et al., 2010). Furthermore, it indicates that this 
method is useful to encapsulate labile molecules (such as growth factors), retaining their 
activity, independently of the polymer matrix used. 
 
3.6. Microparticle macrophage clearance 
Phagocytosis is a process in which macrophages destroy foreign particles in the 
body. Macrophages (phagocytic cells) are an important part of the immune system and 
also an important limitation for drug delivery using polymeric microparticles. In order 
to improve the delivery of VEGF in the ischemic heart, in the present work we prepared 
VEGF-PEGylated microparticles to avoid the clearance of the microparticles by the 
phagocytic cells. 
 
3.6.1. Fluorescence microscopy 
After we incubated J774 cells with particles loaded with Rhodamine B 
isothiocyanate, the uptake of microparticles by macrophages was clearly observable 
under fluorescent microscope. Indeed, significant differences in the fluorescent signal 
inside the cells were detected. In Figure 3 representative images of cells three hours 
post-treatment with PLGA microparticles (A) and PEG-PLGA microparticles (B) are 
shown. When quantifying fluorescence we observed a four-fold increase in particle 
uptake in the case of the PLGA spheres compared to the PEGylated ones (Figure 3 C). 
These results confirmed the efficacy of the surface modification in the reduction of the 
macrophage internalization of the PEGylated microparticles.  
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3.6.2. Flow cytometry 368 
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Microparticle uptake by macrophages induces changes in cellular granularity 
that can be monitored by flow cytometry. Indeed, cells treated with PLGA 
microparticles showed high granularity levels over incubation time (up to 3 hours), 
indicating that a large number of particles had been internalized during that period. 
However, coating the microparticles surface with PEG significantly influenced the 
uptake of the microparticles by the macrophages. Cells receiving surface modified 
particles maintained cell complexity in the same way as the non treated cells (control). 
The differences became significant after incubating the particles for 2 hours in the 
culture medium (Figure 4). Results obtained using flow cytometry confirmed the 
observation made by fluorescence microscopy, demonstrating that PLGA microparticles 
suffer phagocytosis in a more rapid way than PEGylated ones, and consequently 
confirming that particles have been successfully PEGylated.  
 
4. Conclusion 
In this study we encapsulated VEGF in stealth microparticles, using a co-
polymer of PEG and PLGA, with a percentage of PEG adequate to reduce macrophage 
phagocytosis. PEGylated microparticles with high encapsulation efficiency and suitable 
size to be implanted in the myocardium were developed. Importantly, the bioactivity of 
the loaded therapeutic protein was fully preserved. Microparticles whose surface was 
modified by the incorporation of PEG in the formulation illustrated a significantly 
decreased uptake by phagocityc cells. 
In summary, PEGylation could be a useful approach to obtain growth factor-
loaded microparticles for myocardial administration, minimizing their local clearance 
and enhancing the efficacy of the protein therapy in cardiovascular disease. 
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Consequently, the next step will be to test the developed microparticles in vivo, in a rat 
model of myocardial infarction. 
393 
394 
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Figure 1. In vitro release profiles. VEGF released from PLGA and PEG-PLGA MPs is 
represented as a % of the total VEGF load in the particles.  
 
Figure 2. VEGF bioactivity: HUVECs treated with VEGF and VEGF released from the 
microparticles (MPS-VEGF) at the same concentration (10 and 25 ng/ml) proliferate in 
the same ratio when compared to control groups. *P<0.05 and ***P<0.001. 
 
Figure 3. Macrophage uptake studied by fluorescent microscopy. Cells observed under 
fluorescent microscope after incubating them with PLGA (A) and PEG-PLGA (B) 
microparticles containing Rhodamine isocyanate. More Rhodamine is visualized inside 
the cells treated with the PLGA microparticles. This differences are significantly 
different when quantified (C), indicating that these have been phagocyted in a larger 
number than those with the PEG chains in the surface. ***P<0.001. 
 
Figure 4. Macrophage uptake studied by flow cytometry. The highest observed cell 
granularity  value (measured as Side Scatter Cell) has been assigned 100%. Cell 
complexity increases when cells are treated with PLGA microparticles, whereas cells 
treated with culture medium or PEG-PLGA microparticles did not have altered 
complexity three hours after the treatment. *P<0.05 and **P<0.01. 
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